fbpx
CAS Insight

molecules of the month

RevMed KRASG12C Tricomplex Inhibitor

KRAS(G12C)ON-cyclophilin A tri-complex inh.

overcomes KRAS resist. mut. in PDX model

natural product related (sanglifehrin); undiscl.

RM-018

Revolution Medicines, Redwood City, CA

RM-018 revmed tricomplex kras on inhibitor structure cyclophilin recruiter revolution medicines drug hunter molecules of the year
2 mins read

The Revolution Medicines KRASG12C inhibitor, RM-018, “glues” KRASG12C to the highly abundant chaperone protein, cyclophilin A, in a tri-complex (KRAS- inhibitor-cyclophilin A) stabilized by protein-protein interactions. An undisclosed molecule in their pipeline with a related mechanism, RMC-6291, has been reported to be orally bioavailable in multiple species, with oral activity in PDX models. KRAS is a driver of cancer cell growth, and mutants including KRASG12C have been hot targets due to the newfound ability to drug them selectively over wild type KRAS, which is important for healthy cell division. The first KRASG12C inhibitor, sotorasib, was approved in 2021. While GTP-OFF inhibitors of KRASG12C which bind to a switch-II have demonstrated clinical efficacy (including 2020 Small Molecule of the Year Finalist,…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: